Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc (HEPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,716
  • Shares Outstanding, K 5,472
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,930 K
  • 60-Month Beta 1.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.64
Trade HEPA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.48
  • Growth Rate Est. (year over year) +28,806.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +22.13%
on 04/22/24
2.8999 -48.62%
on 04/04/24
-0.8600 (-36.60%)
since 03/22/24
3-Month
1.2200 +22.13%
on 04/22/24
3.4899 -57.31%
on 02/16/24
-0.6200 (-29.38%)
since 01/23/24
52-Week
1.2200 +22.13%
on 04/22/24
20.6600 -92.79%
on 05/23/23
-12.9040 (-89.65%)
since 04/21/23

Most Recent Stories

More News
Hepion Pharmaceuticals (NASDAQ: HEPA) Reports Promising Phase 2 Trial Results for NASH Treatment

Renocofilstat's Positive Outcomes Reinforce Antifibrotic Action Hepion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on AI-assisted therapeutic drug development, recently

HEPA : 1.4900 (+5.67%)
Pre-Market Brief: Stocks Mostly Higher As Investors Await U.S. Inflation Data

March S&P 500 futures (ESH23) are trending up +0.32% this morning after three major U.S. benchmark indices finished the regular session higher as market participants awaited U.S. inflation data for further...

ESH23 : 3,957.05s (-0.09%)
JD-.LN : 120.750 (-1.75%)
HEPA : 1.4900 (+5.67%)
BWEN : 2.15 (-1.38%)
PROK : 2.53 (-6.99%)
CONN : 3.70 (+1.09%)
SHC : 11.38 (+2.61%)
STM : 39.98 (+1.86%)
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders

EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 1.4900 (+5.67%)
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 1.4900 (+5.67%)
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 1.4900 (+5.67%)
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 1.4900 (+5.67%)
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022

- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins – EDISON, N.J., June 15, 2022 (GLOBE...

HEPA : 1.4900 (+5.67%)
Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting

EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...

HEPA : 1.4900 (+5.67%)
CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been...

HEPA : 1.4900 (+5.67%)
Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...

HEPA : 1.4900 (+5.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular...

See More

Key Turning Points

3rd Resistance Point 1.8137
2nd Resistance Point 1.6689
1st Resistance Point 1.5795
Last Price 1.4900
1st Support Level 1.3453
2nd Support Level 1.2005
3rd Support Level 1.1111

See More

52-Week High 20.6600
Fibonacci 61.8% 13.2339
Fibonacci 50% 10.9400
Fibonacci 38.2% 8.6461
Last Price 1.4900
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar